Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 216

1.

Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables.

Ménard S, Valagussa P, Pilotti S, Gianni L, Biganzoli E, Boracchi P, Tomasic G, Casalini P, Marubini E, Colnaghi MI, Cascinelli N, Bonadonna G.

J Clin Oncol. 2001 Jan 15;19(2):329-35.

PMID:
11208823
2.
3.

Tamoxifen chemoprevention of a hormone-independent tumor in the proto-neu transgenic mice model.

Ménard S, Aiello P, Tagliabue E, Rumio C, Lollini PL, Colnaghi MI, Balsari A.

Cancer Res. 2000 Jan 15;60(2):273-5.

4.

Detection of aberrant isotype switch recombination in low-grade and high-grade gastric MALT lymphomas.

Nardini E, Aiello A, Giardini R, Colnaghi MI, Ménard S, Balsari A.

Blood. 2000 Feb 1;95(3):1032-8.

PMID:
10648419
5.

Expression profile of saccharide epitope CaMBr1 in normal and neoplastic tissue from dogs, cats, and rats: implication for the development of human-derived cancer vaccines.

Adobati E, Zacchetti A, Perico ME, Cremonesi F, Rasi G, Vallebona PS, Hagenaars M, Kuppen PJ, Pastan I, Panza L, Russo G, Colnaghi MI, Canevari S.

Histochem J. 1999 Nov;31(11):729-37.

PMID:
10646838
6.
7.

Fluctuation of HER2 expression in breast carcinomas during the menstrual cycle.

Balsari A, Casalini P, Tagliabue E, Greco M, Pilotti S, Agresti R, Giovanazzi R, Alasio L, Rumio C, Cascinelli N, Colnaghi MI, Ménard S.

Am J Pathol. 1999 Nov;155(5):1543-7.

8.

Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors.

Ménard S, Casalini P, Tomasic G, Pilotti S, Cascinelli N, Bufalino R, Perrone F, Longhi C, Rilke F, Colnaghi MI.

Breast Cancer Res Treat. 1999 May;55(2):169-77.

PMID:
10481944
9.

High level antibody response to retrovirus-associated but not to melanocyte lineage-specific antigens in mice protected against B16 melanoma.

Sfondrini L, Morelli D, Bodini A, Colnaghi MI, Ménard S, Balsari A.

Int J Cancer. 1999 Sep 24;83(1):107-12.

11.

Absence of microsatellite instability in breast carcinomas with both p53 and c-erbB-2 alterations.

Formantici C, Orlandi R, Ronchini C, Pilotti S, Ranzani GN, Colnaghi MI, Ménard S.

J Pathol. 1999 Mar;187(4):424-7.

PMID:
10398101
12.

Inhibition of fibronectin-activated migration of microvascular endothelial cells by interleukin-1alpha, tumour necrosis factor alpha and interferon gamma.

Maier JA, Morelli D, Lazzerini D, Mènard S, Colnaghi MI, Balsari A.

Cytokine. 1999 Feb;11(2):134-9.

PMID:
10089134
13.

The 67 kDa laminin receptor as a prognostic factor in human cancer.

Ménard S, Tagliabue E, Colnaghi MI.

Breast Cancer Res Treat. 1998;52(1-3):137-45. Review.

PMID:
10066078
14.

Molecular requirements for attachment of the glycosylphosphatidylinositol anchor to the human alpha folate receptor.

Tomassetti A, Bottero F, Mazzi M, Miotti S, Colnaghi MI, Canevari S.

J Cell Biochem. 1999 Jan 1;72(1):111-8.

PMID:
10025672
15.

Target molecules for immunotherapy of inflammatory breast carcinomas.

Tagliabue E, Pilotti S, Gianni AM, Ménard S, Colnaghi MI.

Eur J Cancer. 1998 Nov;34(12):1982-3. No abstract available.

PMID:
10023328
16.

Ectopic expression of pRb2/p130 suppresses the tumorigenicity of the c-erbB-2-overexpressing SKOV3 tumor cell line.

Pupa SM, Howard CM, Invernizzi AM, De Vecchi R, Giani C, Claudio PP, Colnaghi MI, Giordano A, Ménard S.

Oncogene. 1999 Jan 21;18(3):651-6.

17.

Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival.

Miotti S, Negri DR, Valota O, Calabrese M, Bolhuis RL, Gratama JW, Colnaghi MI, Canevari S.

Int J Cancer. 1999 Feb 19;84(1):62-8.

18.

Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells.

Mezzanzanica D, Canevari S, Mazzoni A, Figini M, Colnaghi MI, Waks T, Schindler DG, Eshhar Z.

Cancer Gene Ther. 1998 Nov-Dec;5(6):401-7.

PMID:
9917095
19.

The 67-kDa laminin receptor originated from a ribosomal protein that acquired a dual function during evolution.

Ardini E, Pesole G, Tagliabue E, Magnifico A, Castronovo V, Sobel ME, Colnaghi MI, Ménard S.

Mol Biol Evol. 1998 Aug;15(8):1017-25.

PMID:
9718729
20.

Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation.

Giani C, Casalini P, Pupa SM, De Vecchi R, Ardini E, Colnaghi MI, Giordano A, Ménard S.

Oncogene. 1998 Jul 30;17(4):425-32.

21.

Evaluation of the balance between angiogenic and antiangiogenic circulating factors in patients with breast and gastrointestinal cancers.

Morelli D, Lazzerini D, Cazzaniga S, Squicciarini P, Bignami P, Maier JA, Sfondrini L, Ménard S, Colnaghi MI, Balsari A.

Clin Cancer Res. 1998 May;4(5):1221-5.

22.

Role of cross-linking agents in determining the biochemical and pharmacokinetic properties of Mgr6-clavin immunotoxins.

Dosio F, Arpicco S, Adobati E, Canevari S, Brusa P, De Santis R, Parente D, Pignanelli P, Negri DR, Colnaghi MI, Cattel L.

Bioconjug Chem. 1998 May-Jun;9(3):372-81.

PMID:
9576812
23.

Formation of the 67-kDa laminin receptor by acylation of the precursor.

Butò S, Tagliabue E, Ardini E, Magnifico A, Ghirelli C, van den Brûle F, Castronovo V, Colnaghi MI, Sobel ME, Ménard S.

J Cell Biochem. 1998 Jun 1;69(3):244-51.

PMID:
9581863
24.

Prognostic value of alpha 6 beta 4 integrin expression in breast carcinomas is affected by laminin production from tumor cells.

Tagliabue E, Ghirelli C, Squicciarini P, Aiello P, Colnaghi MI, Ménard S.

Clin Cancer Res. 1998 Feb;4(2):407-10.

25.

Panning phage antibody libraries on cells: isolation of human Fab fragments against ovarian carcinoma using guided selection.

Figini M, Obici L, Mezzanzanica D, Griffiths A, Colnaghi MI, Winter G, Canevari S.

Cancer Res. 1998 Mar 1;58(5):991-6.

26.

Heregulin beta1 induces the down regulation and the ubiquitin-proteasome degradation pathway of p185HER2 oncoprotein.

Magnifico A, Tagliabue E, Ardini E, Casalini P, Colnaghi MI, Ménard S.

FEBS Lett. 1998 Jan 30;422(2):129-31.

27.

Approaches to implement bispecific antibody treatment of ovarian carcinoma.

Canevari S, Mezzanzanica D, Mazzoni A, Negri DR, Figini M, Ramakrishna V, Bolis G, Colnaghi MI.

Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):187-9. No abstract available.

PMID:
9435870
28.

Binding-induced activation of overexpressed p185HER2 is essential in triggering neuronal differentiation of PC12 cells.

Orlandi R, Formantici C, Colnaghi MI, Ménard S.

J Cell Biochem. 1997 Dec 1;67(3):316-26.

PMID:
9361187
29.

Tumor pretargeting: role of avidin/streptavidin on monoclonal antibody internalization.

Casalini P, Luison E, Ménard S, Colnaghi MI, Paganelli G, Canevari S.

J Nucl Med. 1997 Sep;38(9):1378-81.

30.

Inhibition of tumorigenicity in lung adenocarcinoma cells by c-erbB-2 antisense expression.

Casalini P, Ménard S, Malandrin SM, Rigo CM, Colnaghi MI, Cultraro CM, Segal S.

Int J Cancer. 1997 Aug 7;72(4):631-6.

31.

Comments on Adaptation of the Cellscan technique for the SCM test in breast cancer Rahmani et al., Eur. J. Cancer, 32A, no. 10, pp. 1758-1765 1996.

Birindelli S, Colnaghi MI, Pilotti S.

Eur J Cancer. 1997 Jul;33(8):1333-5. No abstract available.

PMID:
9301465
32.

Efficiency of T cell triggering by anti-CD3 monoclonal antibodies (mAb) with potential usefulness in bispecific mAb generation.

Jacobs N, Mazzoni A, Mezzanzanica D, Negri DR, Valota O, Colnaghi MI, Moutschen MP, Boniver J, Canevari S.

Cancer Immunol Immunother. 1997 Jul;44(5):257-64.

33.

Simultaneous activity of two different mechanisms of folate transport in ovarian carcinoma cell lines.

Miotti S, Bagnoli M, Ottone F, Tomassetti A, Colnaghi MI, Canevari S.

J Cell Biochem. 1997 Jun 15;65(4):479-91.

PMID:
9178098
34.

Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas.

Ménard S, Tomasic G, Casalini P, Balsari A, Pilotti S, Cascinelli N, Salvadori B, Colnaghi MI, Rilke F.

Clin Cancer Res. 1997 May;3(5):817-9.

35.

In vitro mimicry of CaMBr1 tumor-associated antigen by synthetic oligosaccharides.

Adobati E, Panza L, Russo G, Colnaghi MI, Canevari S.

Glycobiology. 1997 Mar;7(2):173-8.

PMID:
9134423
36.

Co-regulation and physical association of the 67-kDa monomeric laminin receptor and the alpha6beta4 integrin.

Ardini E, Tagliabue E, Magnifico A, Butò S, Castronovo V, Colnaghi MI, Ménard S.

J Biol Chem. 1997 Jan 24;272(4):2342-5.

37.

Relationship between folate-binding protein expression and cisplatin sensitivity in ovarian carcinoma cell lines.

Ottone F, Miotti S, Bottini C, Bagnoli M, Perego P, Colnaghi MI, Ménard S.

Br J Cancer. 1997;76(1):77-82.

38.

Production and characterization of monoclonal antibodies directed against the laminin receptor precursor.

Butò S, Ghirelli C, Aiello P, Tagliabue E, Ardini E, Magnifico A, Montuori N, Sobel ME, Colnaghi MI, Ménard S.

Int J Biol Markers. 1997 Jan-Mar;12(1):1-5.

PMID:
9176710
39.

Intratibial injection of an anti-doxorubicin monoclonal antibody prevents drug-induced myelotoxicity in mice.

Morelli D, Ménard S, Cazzaniga S, Colnaghi MI, Balsari A.

Br J Cancer. 1997;75(5):656-9.

40.

Peptide G, containing the binding site of the 67-kDa laminin receptor, increases and stabilizes laminin binding to cancer cells.

Magnifico A, Tagliabue E, Butó S, Ardini E, Castronovo V, Colnaghi MI, Ménard S.

J Biol Chem. 1996 Dec 6;271(49):31179-84.

41.

CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.

Mazzoni A, Mezzanzanica D, Jung G, Wolf H, Colnaghi MI, Canevari S.

Cancer Res. 1996 Dec 1;56(23):5443-9.

42.

New SCM (structuredness of the cytoplasmatic matrix)-based approach in breast cancer detection.

Birindelli S, Colnaghi MI, Pilotti S.

Tumori. 1996 Nov-Dec;82(6):550-3.

PMID:
9061062
43.

Laminin activates the p185HER2 oncoprotein and mediates growth inhibition of breast carcinoma cells.

Tagliabue E, Ardini E, Pellegrini R, Campiglio M, Bufalino R, Jeschke M, Groner B, Colnaghi MI, Ménard S.

Br J Cancer. 1996 Nov;74(9):1427-33.

44.

Apoptosis of hair follicle cells during doxorubicin-induced alopecia in rats.

Cece R, Cazzaniga S, Morelli D, Sfondrini L, Bignotto M, Ménard S, Colnaghi MI, Balsari A.

Lab Invest. 1996 Oct;75(4):601-9.

PMID:
8874390
45.

Tumor-necrosis-factor-induced fibroblast growth factor-1 acts as a survival factor in a transformed endothelial cell line.

Maier JA, Morelli D, Ménard S, Colnaghi MI, Balsari A.

Am J Pathol. 1996 Sep;149(3):945-52.

46.

No additive impact on patient survival of the double alteration of p53 and c-erbB-2 in breast carcinomas.

Ménard S, Casalini P, Pilotti S, Cascinelli N, Rilke F, Colnaghi MI.

J Natl Cancer Inst. 1996 Jul 17;88(14):1002-3. No abstract available.

PMID:
8667419
47.

Clavin, a type-1 ribosome-inactivating protein from Aspergillus clavatus IFO 8605. cDNA isolation, heterologous expression, biochemical and biological characterization of the recombinant protein.

Parente D, Raucci G, Celano B, Pacilli A, Zanoni L, Canevari S, Adobati E, Colnaghi MI, Dosio F, Arpicco S, Cattel L, Mele A, De Santis R.

Eur J Biochem. 1996 Jul 15;239(2):272-80.

48.
49.

Local concentration of folate binding protein GP38 in sections of human ovarian carcinoma by in vitro quantitative autoradiography.

Li PY, Del Vecchio S, Fonti R, Carriero MV, Potena MI, Botti G, Miotti S, Lastoria S, Menard S, Colnaghi MI, Salvatore M.

J Nucl Med. 1996 Apr;37(4):665-72.

50.

Anti-idiotypic response to antigrowth factor receptor monoclonal antibodies.

Tosi E, Valota O, Canevari S, Adobati E, Casalini P, Perez P, Colnaghi MI.

Eur J Cancer. 1996 Mar;32A(3):498-505.

PMID:
8814698

Supplemental Content

Loading ...
Support Center